Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant - Wikidata - awgldk - TriplyDB

Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

http://www.wikidata.org/entity/Q35319290

about

Vaccine adjuvants as potential cancer immunotherapeutics Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE)Cancer/testis antigens, gametogenesis and cancer Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients Identification and analysis of tumour-associated antigens in hepatocellular carcinoma.Anchor side chains of short peptide fragments trigger ligand-exchange of class II MHC molecules Melanoma: tumor microenvironment and new treatments.Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Trial watch: Peptide vaccines in cancer therapy TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma.NY-ESO-1 immunotherapy for multiple myeloma.Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.Promising particle-based vaccines in cancer therapy.Systematic identification of immunodominant CD4+ T cell responses to HpaA in Helicobacter pylori infected individuals.Vaccine-induced antibody responses in patients with carcinoma.Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro.NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population.Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.New hypotheses for large-scale epigenome alterations in somatic cancer cells: a role for male germ-cell-specific regulators.Identification of Two Lpp20 CD4+ T Cell Epitopes in Helicobacter pylori-Infected Subjects.

P2860

Q26752522-E3764BFA-5840-497A-B1E3-97C4D727C4EC Q28476101-2720DD15-FA11-40EE-A90E-529943DBE269 Q29616129-B9056323-CB03-4522-83C9-712111409594 Q30358114-9FFE09BC-CB97-4783-8F36-1DB21DA75BAA Q33212678-49FC8616-96BD-46C6-A747-43D990318DBF Q33324394-8B8943BD-54F1-4FC6-9159-6C9A7A7408D8 Q33675676-996A55E3-8F0F-4542-8627-F8A283243AA1 Q33997622-0B02213D-A130-408A-B6B0-490BCA9922D2 Q34388367-D6B60C59-2798-4EC2-AEF7-060FB0BD8575 Q34461203-AFF9652D-6440-4AB8-903F-0AC37BEB6EE7 Q35039508-9DC9DC17-8EA7-496C-919C-79F1F494E1F2 Q35067995-4BBB65DF-0FD1-4F95-9CFB-21902ED516FE Q35863071-B51473AC-DD70-4F7A-B171-4C5A4745CCE7 Q36471827-675C699B-7C31-4E4C-BB43-905E4D1B274D Q36476100-0F0E4DCC-8794-4955-A76C-73392B9C5E41 Q36615203-2EB02E72-4378-43AB-866A-E67E3C5CB52F Q36637651-935649A6-6180-4A64-BA95-112F7EE67F27 Q37088532-3FA7FF64-E72E-480A-8063-3C840868D4B0 Q37259642-BDBCC72A-29A0-4A36-9E7E-60F7E301D036 Q37688064-7F037A53-823E-4B4D-A620-BB3025E077AB Q37762272-231FCF40-7FAB-4C95-AC56-B863A471D59F Q39131858-243B92B6-23A3-4BC5-9145-A7860FACD050 Q39150340-5A5F77AF-4E62-4C72-9FFB-B96540EF4DA4 Q39162824-8E22CA64-7C86-4B62-8C43-5A3D8EABE476 Q39325954-636479B4-B8DB-46EC-A6C2-6AC03E617AF7 Q40135212-D0E61B30-08DB-4097-A8A3-19DF724C6641 Q40375552-AF86D184-4CA3-4B9C-88CC-8EA8E89704C6 Q40448718-ECC67610-FF94-40A4-ACEA-14C1DA8C8921 Q41184340-B0542B87-A6A5-4743-8348-C0A11E3E234D Q41894814-BB0F0D7D-62CA-49CE-9782-30E9AC3B6AA2 Q44545688-DA4D74F7-4003-4F9C-8632-83B097AE944D Q53306166-53EA2165-99A1-462B-8317-19208FA4FC44 Q55545288-1770237A-6C05-424D-A45D-F86C84064A26

P2860

Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

http://www.wikidata.org/entity/Q35319290

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant

@ast

Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant

@en

type

label

Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant

@ast

Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant

@en

prefLabel

Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant

@ast

Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant

@en

P1433

Q35319290-669949ED-D19B-429B-80A2-E0DF5F150187

P1476

Q35319290-4C695AD8-D84B-4BC8-A1A2-C7D567B6C809

P2093

Q35319290-0099F5EA-E344-4042-B0F9-F5E70B1C160C

Q35319290-0C377C6D-62A1-481C-9E19-52BAF182EC49

Q35319290-137AE6C7-9135-44B1-8A97-339F8239CADF

Q35319290-2F0D2305-F9E3-42E3-B4E6-40EC0708E171

Q35319290-3C20F38F-E30D-4450-84BC-F701EC513329

Q35319290-4F9C2941-5143-4710-B7C5-58B297896BEB

Q35319290-52DDE866-C7D2-4417-A0C3-94B4BA763E57

Q35319290-7825CE06-D7ED-447D-9882-FC6DA9F44A2B

Q35319290-8F6C1586-5DE5-4271-80D9-8CCD2A774762

Q35319290-97E38523-FE70-451E-917E-3F4C700FF08E

P2860

Q35319290-14CF55B2-BBCF-43F7-AB6A-0CF1A0EF52E9

Q35319290-18D02D03-AD3B-4EDE-BA00-65064865D547

Q35319290-2161C65F-8320-4A19-B2E3-6C607A472D01

Q35319290-3E214C84-B3C8-4FD7-9823-CE52D4A04925

Q35319290-4E86D8B7-FB61-4627-8E2F-F7B9DE2C6EF4

Q35319290-599B9A51-99B9-420D-85F5-C1D54AD983DD

Q35319290-5C67F3FB-DC25-4FE2-A393-149434FDFED2

Q35319290-640A3A0B-9900-41C8-A0C2-50C147DD7361

Q35319290-7626E5C0-3A6A-4056-B27D-857E3E6DA2F3

Q35319290-77D22518-B133-4021-80E9-1CF1D7E9C225

P304

Q35319290-6923FA97-44A8-4A88-9C58-4A6AB12CB683

P31

Q35319290-D257197B-F6BC-491A-987F-FCB6B090D358

P356

Q35319290-A92C3A52-39FD-4780-A7B9-10851E83EB86

P407

Q35319290-0956BB72-6621-422A-9DEA-280C64F2A0CA

P433

Q35319290-4892C48A-3697-401F-A729-DEC5E1B623F8

P478

Q35319290-006ADF0A-3D2B-4848-AE1C-D3266C1CE89B

P50

Q35319290-A3658526-3A9E-4D61-90D3-944195CC88E5

Q35319290-CA7B986E-6AA0-4DB3-A2D2-4A1874A65AD8

Q35319290-E5A022C3-8900-4874-B56C-B338D099F932

P577

Q35319290-1A281E67-FF91-4234-89E8-8BC7E102B98C

P5875

Q35319290-60FBE5C9-1B2B-421D-A96B-4D590E48B339

P698

Q35319290-AECCC76F-3A61-44D6-978C-333103C4E5E4

P921

Q35319290-AEC1B67A-CCA2-45AC-B080-17DB6430A8F4

P932

Q35319290-8B130C24-3865-4AEF-B7BC-B156E81C7269

P356

PNAS.0403271101

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant

@en

P2093

Eugene Maraskovsky

http://www.w3.org/2001/XMLSchema#string

He-Cheng Zhu

http://www.w3.org/2001/XMLSchema#string

Heather Goldie

http://www.w3.org/2001/XMLSchema#string

Heather Jackson

http://www.w3.org/2001/XMLSchema#string

Ian D Davis

http://www.w3.org/2001/XMLSchema#string

Jonathan Cebon

http://www.w3.org/2001/XMLSchema#string

Lena Miloradovic

http://www.w3.org/2001/XMLSchema#string

Lloyd J Old

http://www.w3.org/2001/XMLSchema#string

Mark Rizkalla

http://www.w3.org/2001/XMLSchema#string

Nektaria Dimopoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide

HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles.

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

A listing of human tumor antigens recognized by T cells.

Novel role of CD8(+) T cells and major histocompatibility complex class I genes in the generation of protective CD4(+) Th1 responses during retrovirus infection in mice.

Rational approaches to human cancer immunotherapy.

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

P304

9363-9368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0403271101

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

James McCluskey

Kelly-Anne Masterman

Nicole A Mifsud

P577

2004-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8510835

http://www.w3.org/2001/XMLSchema#string

P698

15197261

http://www.w3.org/2001/XMLSchema#string

P921

P932

438982

http://www.w3.org/2001/XMLSchema#string